NCT00252889 - Doxil Topotecan Doublet Cancer Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

March 31, 2006

Study Completion Date

June 30, 2008

Conditions

Small Cell Lung CancerPancreatic CancerHead and Neck CancerGastric CancerEsophageal Cancer

Interventions

DRUG

Topotecan and pegylated doxorubicin

Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients

Trial Locations (1)

Christiana Care Health Services, Newark